Altria Group Inc. (0R31)
London Exchange · UK · prices in USD · close of 21 Oct 2026
Key indicators
| Last close | USD 66.40 |
|---|---|
| 52-week range | 54.50 – 77.01 |
| Return, 1 month / 3 months | −3.3% / +0.0% |
| Return, 1 year / 3 years | +4.2% / +93.1% |
| Trend | Below its 200-day average |
| RSI (14) | 45 |
| Volatility (1 year) | 47.5% |
| Worst drawdown (1 year) | -14.3% |
| Average daily value traded | 0.51M USD |
| Dividend yield | 1.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Altria Group is an American tobacco company based in Richmond, Virginia. It makes and markets cigarettes, including the Marlboro brand, along with smokeless tobacco products such as chewing tobacco and snuff, and it also offers cigars and e-vapor products. Its customers are adult tobacco consumers, and its products are sold through wholesalers and retailers across the United States. The company also holds an investment in a large brewing business.
The shares are listed on the London Exchange in UK under the code 0R31, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Altria Group Inc. (0R31) trades on the London Exchange in UK. It last closed at USD 66.40 on 21 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 1,925 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 4.2% and over the last three months it rose 0.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 52 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -0.5% | ||
| From 52-week high | -11.6% | ||
| Momentum | 51 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 0.0% | ||
| 6-month return | 0.0% | ||
| 12-month return, skipping the last month | 7.8% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 47.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.3% | ||
| Liquidity | 46 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.51M USD | ||
| Zero-volume days | 1.7% | ||
| Income | 48 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.6% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −8.9% |
|---|---|
| 1 month | −3.3% |
| 3 months | +0.0% |
| 6 months | +0.0% |
| 1 year | +4.2% |
| 3 years | +93.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 67.42 / 66.71 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.49 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Dec 2025 | USD 1.0600 |
| 12 Sep 2025 | USD 1.0600 |
| 16 Jun 2025 | USD 1.0200 |
| 24 Mar 2025 | USD 1.0200 |
| 24 Dec 2024 | USD 1.0200 |
| 13 Sep 2024 | USD 1.0200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.